艾素或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的临床对照研究

目的比较艾素（多烯紫杉醇）或长春瑞滨联合顺铂方案对晚期非小细胞肺癌（NSCLC）的疗效和副作用。方法选取初治晚期NSCLC病人66例,分别应用TP（艾素＋顺铂）、NP（长春瑞滨＋顺铂）方案进行治疗。每例均完成两周期化疗后评价疗效及副作用。结果TP、NP组病人近期有效率分别为40.6%、38.2%,两组比较差异无显著性（P〉0.05）。两组副作用均以骨髓抑制、恶心呕吐为主,但均未影响治疗。两组均无化疗相关死亡发生。结论TP、NP均为治疗晚期NSCLC有效且耐受性较好的方案。

CLINICAL STUDY OF COMBINED CHEMOTHERAPY OF CISPLATIN PLUS TAXOTERE OR VINORELBINE FOR ADVANCED NON- SMALL CELL LUNG CANCER

Objective To evaluate the efficacy and toxicity of combined chemotherapy of cisplatin plus taxotere or vi norelbine for advanced non-small cell lung cancer （NSCLC）. Methods A total of 66 initially treated patients with advanced NSCLC were enrolled in this study and treated by TP （cisplatin plus taxotere） and NP （cisplatin plus vinorelbine）. The efficacy and side effects were analyzed after two cycles of therapy. Results The short term response rates （CR-PR） were 40.6% and 38.2% for the TP group and the NP group, the difference was not significat between the two groups （P〉0.05）. The major side effects were myelo-suppression, nausea and/or vomiting, but did not impact the therapy. No chemotherapy-related death was recorded. Conclusion The combined regimens of TP and NP are effective and well tolerated for advanced NSCLC patients.